Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis

Respiratory Medicine CME

Volumn 3, Issue 2, 2010, Pages 51-61

  Ahmad, Suhail ^a   Mokaddas, Eiman ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Management; MDR TB; Rapid diagnosis; Treatment

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMIKACIN; AMINOSALICYLIC ACID; BACTERIAL DNA; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; KATG PROTEIN; LEVOFLOXACIN; LUCIFERASE; MOXIFLOXACIN; MYCOLIC ACID; NITRATE REDUCTASE; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RESAZURIN; RIFABUTIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; STREPTOMYCIN; UNINDEXED DRUG; VIOMYCIN;

ACID FAST BACTERIUM; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CODON; DEVELOPING COUNTRY; DNA REPLICATION; DNA SEQUENCE; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; EPIDEMIC; EXTRAPULMONARY TUBERCULOSIS; FALSE POSITIVE RESULT; GENE MUTATION; HUMAN; HYBRIDIZATION; MICROARRAY ANALYSIS; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PUBLIC HEALTH; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SHORT COURSE THERAPY; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 77956045062     PISSN: 17550017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedc.2010.08.001     Document Type: Article

References (132)

1. World Health Organization Global tuberculosis control: surveillance, planning and financing 2008, WHO report 2008. WHO/HTM/TB/2008.393, WHO, Geneva, Switzerland.
2. Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., Dye C. Tuberculosis. Lancet 2003, 362:887-899.
3. Wells C.D., Cegielski J.P., Nelson L.J., et al. HIV infection and multidrug-resistant tuberculosis-the perfect storm. J Infect Dis 2007, 196(Suppl. 1):S86-107.
4. Medical Research Council Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council Investigation. Br Med J 1948, 4582:769-782.
5. Mitchison D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985, 66:219-225.
6. Mitchison D.A. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 2005, 171:699-706.
7. Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep 2003, 52:1-77. American Thoracic Society, CDCCDC, Infectious Disease Society of AmericaInfectious Disease Society of America.
8. Palaci M., Dietze R., Hadad D.J., et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol 2007, 45:4064-4066.
9. World Health Organization Anti-tuberculosis drug resistance in the world: fourth Global report 2008, WHO/HTM/TB/2008.394, WHO, Geneva, Switzerland.
10. Drobniewski F., Balabanova Y., Ruddy M. Rifampin- and multidrug-resistant tuberculosis in Russian civilians and prison inmates: dominance of the Beijing strain family. Emerg Infect Dis 2002, 8:1320-1326.
11. Kimerling M.E., Phillips P., Patterson P., Hall M., Robinson C.A., Dunlap N.E. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998, 113:1178-1183.
12. Mokaddas E., Ahmad S., Abal A.T., Al-Shami A.S. Molecular fingerprinting reveals familial transmission of rifampin-resistant tuberculosis in Kuwait. Ann Saudi Med 2005, 25:150-153.
13. Aziz M.A., Wright A., Laszlo A., et al. for the WHO/International Union Against Tuberculosis and Lung Disease global project on anti-tuberculosis drug resistance surveillance. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006, 368:2142-2154.
14. Zignol M., Hosseini M.S., Wright A., et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006, 194:479-485.
15. Mitnick C.D., Castro K.G., Harrington M., Sacks L.V., Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007, 4:e292.
16. Centers for Disease Control and Prevention (CDC) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006, 55:301-305.
17. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009, 7:81-87.
18. Gandhi N.R., Moll A., Sturn A.W., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1554-1556.
19. Zhang Y., Heym B., Allen B., Young D., Cole S.T. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992, 358:591-593.
20. Telenti A., Imboden P., Marchesi F., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650.
21. Vilcheze C., Wang F., Arai M., et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 2006, 12:1027-1029.
22. Ramaswamy S., Musser J.M. Molecular genetics basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998, 79:3-29.
23. Johnson R., Streicher E., Louw G., Warren R.M., van Helden P.D., Victor T.C. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006, 8:97-111.
24. Ramaswamy S., Reich R., Dou S., et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003, 47:1241-1250.
25. Abal A.T., Ahmad S., Mokaddas E. Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. Microb Drug Resist 2002, 8:99-105.
26. Mokrousov I., Narvskaya O., Otten T., Limeschencko E., Steklova L., Vyshnevskiy B. High prevalence of Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates of from Northwestern Russia, 1996-2001. Antimicrob Agents Chemother 2002, 46:1417-1424.
27. Silva M.S.N., Senna S.G., Ribeiro M.O., et al. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol 2003, 41:4471-4474.
28. Hazbon M.H., Brimacombe M., del Valle M.B., et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006, 50:2640-2649.
29. Mokaddas E., Ahmad S., Samir I. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005. Int J Tuberc Lung Dis 2008, 12:319-325.
30. Van Rie A., Warren R., Mshanga I., et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol 2001, 39:636-641.
31. Siddiqi N., Shamim M., Hussain S., et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob Agents Chemother 2002, 46:443-450.
32. Afanas'ev M.V., Ikryannikova L.N., Il'ina E.N., et al. Molecular characteristics of rifampicin- and isoniazid resistant Mycobacterium tuberculosis isolates from Russian Federation. J Antimicrob Chemother 2007, 59:1057-1064.
33. Ahmad S., Mokaddas E., Fares E. Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn Microbiol Infect Dis 2002, 44:245-252.
34. Sheng J., Li J., Sheng G., et al. Characterization of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis from eastern China. J Appl Microbiol 2008, 105:904-911.
35. Heep M., Brandstatter B., Rieger U., et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol 2001, 39:107-110.
36. Ahmad S., Mokaddas E. The occurrence of rare rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from Kuwait. Int J Antimicrob Agents 2005, 26:205-212.
37. Yang B., Koga H., Ohno H., et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998, 42:621-628.
38. Cavusoglu C., Karaca-Derici Y., Bilgic A. In-vitro activity of rifabutin against rifampicin-esistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004, 10:662-665.
39. Scorpio A., Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996, 2:662-667.
40. Sekiguchi J.I., Nakamura T., Miyoshi-Akiyama T., et al. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains. J Clin Microbiol 2007, 45:2802-2807.
41. Ramaswamy S., Amin A.G., Koksel S., et al. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000, 44:326-336.
42. Telenti A., Phillipp W., Sreevatsan S., et al. The emb operon, a unique gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997, 3:567-570.
43. Safi H., Sayers B., Hazbon M.H., Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid and rifampin. Antimicrob Agents Chemother 2008, 52:2027-2034.
44. Starks A.M., Gumusboga A., Plikaytis B.B., Shinnick T.M., Posey J.E. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009, 53:1061-1066.
45. Ahmad S., Jaber A.A., Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis 2007, 87:123-129.
46. Sreevatsan S., Pan X., Stockbauer K.E., Williams D.L., Kreisworth B.N., Musser J.M. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic locations. Antimicrob Agents Chemother 1996, 40:1024-1026.
47. Cooksey R.C., Morlock G.P., McQueen A., Glickman S.E., Crawford J.T. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City. Antimicrob Agents Chemother 1996, 40:1186-1188.
48. Maus C.E., Pilkaytis B.B., Shinnick T.M. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49:3192-3197.
49. Maus C.E., Pilkaytis B.B., Shinnick T.M. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49:571-577.
50. Rustomjee R., Lienhardt C., Kanyok T., et al. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-138.
51. Ginsburg A.S., Grosset J.H., Bishai W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003, 3:432-442.
52. Pitaksajjakul P., Wongwit W., Punprasit W., Eampokalap B., Peacock S., Ramasoota P. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health 2005, 36:228-237.
53. Wang J.Y., Lee L.N., Lai H.C., et al. Fluoroquinolones resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007, 59:860-865.
54. Morlock G.P., Metchock B., Sikes D., Crawford J.T., Cooksey R.C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003, 47:3799-3805.
55. Brodie D., Schluger N.W. The diagnosis of tuberculosis. Clin Chest Med 2005, 26:247-271.
56. Palomino J.C. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J 2005, 26:339-350.
57. Cheng V.C.C., Yew W.W., Yuen K.Y. Molecular diagnostics in tuberculosis. Eur J Clin Microbiol Infect Dis 2005, 24:711-720.
58. Mokaddas E., Ahmad S. Development and evaluation of a multiplex PCR for rapid detection and differentiation of Mycobacterium tuberculosis complex members from non-tuberculous mycobacteria. Jap J Infect Dis 2007, 60:140-144.
59. Tortoli E., Mariottini A., Mazarelli G. Evaluation of INNO-LiPA MYCOBACTERIA v2: improved reverse hybridization multiple DNA probe assay for mycobacterial identification. J Clin Microbiol 2003, 41:4418-4420.
60. Russo C., Tortoli E., Manichella D. Evaluation of the new Genotype Mycobacterium assay for identification of mycobacterial species. J Clin Microbiol 2006, 44:334-339.
61. Mokaddas E., Ahmad S. Species spectrum of nontuberculous mycobacteria causing infections in Kuwait. Curr Microbiol 2008, 56:413-417.
62. Tortoli E., Benedetti M., Fontanelli A., Simonetti T. Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion. J Clin Microbiol 2002, 40:607-610.
63. Scarparo C., Ricordi P., Ruggiaro G., Piccoli P. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J Clin Microbiol 2004, 42:1109-1114.
64. Piersimoni C., Olivieri A., Benacchio L., Scarparo C. Current perspective on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol 2006, 44:20-28.
65. Rusch-Gerdes S., Pfyffer G.E., Casal M., Chadwick M., Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line and newer antimicrobials. J Clin Microbiol 2006, 44:688-692.
66. Moore D.A.J., Evans C.A.W., Gilman R.H., et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006, 355:1539-1550.
67. Shiferaw G., Woldeamanuel Y., Gebeyehu M., Girmachew F., Demessie D., Lemma E. Evaluation of microscopic observation drug susceptibility assay for the detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2007, 45:1093-1097.
68. Ejigu G.S., Woldeamanuel Y., Shah N.S., Gebeyehu M., Silassie A., Lemma E. Microscopic-observation drug susceptibility assay provides rapid and reliable identification of MDR-TB. Int J Tuberc Lung Dis 2008, 12:332-337.
69. Palomino J.C., Martin A., Portaels F. Rapid drug resistance detection in Mycobacterium tuberculosis. a review of colourimetric methods. Clin Microbiol Infect 2007, 13:754-762.
70. Abate G., Aseffa A., Selassie A., et al. Direct colorimetric assay for rapid detection of rifampin-resistant Mycobacterium tuberculosis. J Clin Microbiol 2004, 42:871-873.
71. Martin A., Portaels F., Palomino J.C. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2007, 59:175-183.
72. Affolabi D., Odoun M., Martin A., Palomino J.C., Anagonou S., Portaels F. Evaluation of direct detection of Mycobacterium tuberculosis rifampin resistance by a nitrate reductase assay applied to sputum samples in Cotonou, Benin. J Clin Microbiol 2007, 45:2123-2125.
73. Hazbon M.H., Guarin N., Ferro B.E., et al. Photographic and luminometric detection of luciferase reporter phages for susceptibility testing of Mycobacterium tuberculosis isolates. J Clin Microbiol 2003, 41:4865-4869.
74. Banaiee N., January V., Barthus C., et al. Evaluation of semiautomated reporter phage assay for susceptibility testing of Mycobacterium tuberculosis isolates in South Africa. Tuberculosis 2008, 88:64-68.
75. Traore H., van Deun A., Shamputa I.C., Rigouts L., Portaels F. Direct detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay. J Clin Microbiol 2006, 44:4384-4388.
76. Hillemann D., Gerdes R.S., Richter E. Evaluation of Genotype MTBDR plus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007, 45:2635-2640.
77. Feasibility of the GenoType MTBDR sl assay for fluoroquinolone, amikacin-capreomycin and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009, 47:1767-1772.
78. Mokrousov I., Bhanu N.V., Suffys P.N., Kadival G.V., Yap S.F., Cho S.N., et al. Multicenter evaluation of reverse line blot assay for detection of drug resistance in Mycobacterium tuberculosis clinical isolates. J Microbiol Methods 2004, 57:323-335.
79. Sougakoff W., Rodrigues M., Truffot-Pernot C., et al. Use of a high-density DNA probe array for detecting mutations involved in rifampicin resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2004, 10:289-294.
80. Bergval I.L., Vijzelaar R.N.C.P., Dalla Costa E.R., et al. Development of multiplex assay for rapid characterization of Mycobacterium tuberculosis. J Clin Microbiol 2008, 46:689-699.
81. Cockerill F.R., Uhl J.R., Temesgen Z., et al. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis 1995, 171:240-245.
82. Ahmad S., Mokaddas E., Jaber A.A. Rapid detection of ethambutol-resistant Mycobacterium tuberculosis strains by PCR-RFLP targeting embB codons 306 and 497 and iniA codon 501 mutations. Mol Cell Probes 2004, 18:299-306.
83. Ahmad S., Mokaddas E. Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East. Int J Antimicrob Agents 2004, 23:473-479.
84. Marttila H.J., Makinen J., Marjamaki M., Soini H. Prospective evaluation of pyrosequencing for the rapid detection of isoniazid and rifampin resistance in clinical Mycobacterium tuberculosis isolates. Eur J Clin Microbiol Infect Dis 2009, 28:33-38.
85. Ruiz M Torres M.J., Llanos A.C., Arroyo A., Palomares J.C., Aznar J. Direct detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis in auramine-rhodamine-positive sputum specimens by real-time PCR. J Clin Microbiol 2004, 42:1585-1589.
86. Espasa M., Gonzales-Martin J., Alcaide F., et al. Direct detection in clinical samples of multiple gene mutations causing resistance of Mycobacterium tuberculosis to isoniazid and rifampicin using fluorogenic probes. J Antimicrob Chemother 2005, 55:860-865.
87. Viveiros M., Leandro C., Rodrigues L., et al. Direct application of the INNO-LiPA Rif. TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. J Clin Microbiol 2005, 43:4880-4884.
88. Vijdea R., Stegger M., Sosnovskaja A., Andersen A.B., Thomsen V.O., Bang D. Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis 2008, 27:1079-1086.
89. Evans J., Stead M.C., Nicol M.P., Segal H. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. J Antimicrob Chemother 2009, 63:11-16.
90. Giannoni F., Iona E., Sementilli F., Brunori L., Pardini M., Migliori G.B., et al. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. J Clin Microbiol 2005, 49:2928-2933.
91. Kim S.Y., Park Y.J., Song E., et al. Evaluation of the CombiChip Mycobacteria Drug-Resistance detection DNA chip for identifying mutations associated with resistance to isoniazid and rifampin in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 2006, 54:203-210.
92. Donald P.R., Diacon A.H. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis 2008, 88:S75-S83.
93. Fortun J., Martin-Davila P., Navas E., et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005, 56:180-185.
94. Dietze R., Hadad D.J., McGee B., et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008, 178:1180-1185.
95. Espinal M.A., Kim S.J., Suarez P.G., et al. Standard short-course chemotherapy for drug-resistant tuberculosis. JAMA 2000, 283:2537-2545.
96. Mak A., Thomas A., Sel Granado M., Zalekis R., Mouzafarova N., Menzies D. Influence of multidrug-resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008, 178:306-312.
97. Lew W., Pai M., Oxdale O., Martin D., Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008, 149:123-134.
98. Fischl M.A., Daikos G.L., Uttamchandani R.B., et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann Intern Med 1992, 117:184-190.
99. Park M.M., Davis A.L., Schluger N.W., Cohen H., Rom W.N. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996, 153:317-324.
100. Turett G.S., Telzak E.E., Torian L.V., et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995, 21:1238-1244.
101. Mukherjee J.S., Rich M.L., Socci A.R., et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004, 363:474-481.
102. Furin J. The clinical management of drug-resistant tuberculosis. Curr Opin Pulm Med 2007, 13:212-217.
103. Mitnick C.D., Appleton S.C., Shin S.S. Epidemiology and treatment of multidrug-resistant tuberculosis. Semin Respir Crit Care Med 2008, 29:499-524.
104. Harries A.D., Boxshall M., Phiri S., Kwanjana J. Providing HIV care for tuberculosis patients in sub-Saharan Africa. Int J Tuberc Lung Dis 2006, 10:1306-1311.
105. Rich M.L., Socci A.R., Mitnick C.D., et al. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis 2006, 10:290-296.
106. Perkins M.D., Smith L.M. Facing the crises: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 2007, 196(Suppl. 1):S15-S27.
107. Leimane V., Riekstina V., Holtz T.H., et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005, 365:318-326.
108. Saravia J.C., Appleton S.C., Rich M.L., Sarria M., Bayona J., Becerra M.C. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 2005, 9:421-429.
109. Shin S.S., Yagui M., Ascencios L., et al. Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerg Infect Dis 2008, 15:701-708.
110. Holtz T.H., Sternberg M., Kammerer S., et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006, 144:650-659.
111. Han L.L., Sloutsky A., Canales R., et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric treatment with standardized regimens. Int J Tuberc Lung Dis 2005, 9:818-821.
112. Dominguez-Castellano A., Muniain M.A., Muniain M.A., et al. Factors associated with time to sputum smear conversion in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2003, 7:432-438.
113. Shin S.S., Pasechnikov A.D., Gelmanova I.Y., et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006, 10:402-408.
114. Riekstina V., Leimane V., Holtz T.H., Leimans J., Wells C.D. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. Int J Tuberc Lung Dis 2007, 11:585-587.
115. Van Deun A., Salim M.A., Das A.P., Bastian I., Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004, 8:560-567.
116. Nathanson E., Lambregts-van Weezenbeek C., Rich M.L., et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006, 12:1389-1397.
117. Tupasi T.E., Gupta R., Quelapio M.I., et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006, 3:e352.
118. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis 2006, WHO, Geneva, Switzerland.
119. Mitchison D.A. Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Semin Respir Crit Care Med 2004, 25:307-315.
120. Connolly L.E., Edelstein P.H., Ramakrishnan L. Why is long-term therapy required to cure tuberculosis. PLoS Med 2007, 4:e120.
121. Salomon J.A., Lloyd-Smith J.O., Getz W.M., et al. Prospects for advancing tuberculosis control through novel therapies. PLoS Med 2006, 3:e273.
122. Ginsberg A.M. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008, 29:552-559.
123. Stover C.K., Warrener P., VanDevanter D.R., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405:962-966.
124. Nueremberger E., Tyagi S., Tasneen T., et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008, 52:1522-1524.
125. Matsumoto M., Hashizume H., Tomishige T., et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006, 3:e466.
126. Manjunatha U.H., Boshoff H., Dowd C.S., et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006, 103:431-436.
127. Andries K., Verhasselt P., Guillemont J., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
128. Lounis N., Veziris N., Chauffour A., Truffot-Pernot C., Andries K., Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006, 50:3543-3547.
129. Protopopova M., Hanrahan C., Nikonenko B., et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005, 56:968-974.
130. Nikonenko B.V., Protopopova M.N., Samala R., Einck L., Nacy C.A. Drug therapy of experimental TB: improved outcome by combining SQ109, a new diamine antibiotic with existing TB drugs. Antimicrob Agents Chemother 2007, 51:1563-1565.
131. Villar R., Vicente E., Solano B., et al. In vitro and in vivo antimycobacterial acitivities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J Antimicrob Chemother 2008, 62:547-554.
132. Lilienkampf A., Mao J., Wan B., Wang Y., Franzblau S.G., Kozikowski A.P. Structure-activity relationships for a series of quinoline-based compounds against replicating and nonreplicating. J Med Chem 2009, 52:2109-2118.